Your browser is no longer supported. Please, upgrade your browser.
Settings
XERS Xeris Pharmaceuticals, Inc. daily Stock Chart
XERS [NASD]
Xeris Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.61 Insider Own2.80% Shs Outstand32.79M Perf Week29.88%
Market Cap158.25M Forward P/E- EPS next Y-1.83 Insider Trans17.58% Shs Float- Perf Month185.19%
Income-129.50M PEG- EPS next Q-0.73 Inst Own70.20% Short Float- Perf Quarter33.09%
Sales4.30M P/S36.80 EPS this Y-66.60% Inst Trans46.76% Short Ratio3.23 Perf Half Y-30.45%
Book/sh0.83 P/B6.49 EPS next Y37.00% ROA-106.30% Target Price- Perf Year-52.59%
Cash/sh3.30 P/C1.63 EPS next 5Y- ROE-323.80% 52W Range1.42 - 12.94 Perf YTD-23.55%
Dividend- P/FCF- EPS past 5Y- ROI-167.70% 52W High-58.35% Beta-
Dividend %- Quick Ratio4.70 Sales past 5Y- Gross Margin20.40% 52W Low279.58% ATR0.54
Employees199 Current Ratio4.80 Sales Q/Q800.00% Oper. Margin- RSI (14)75.86 Volatility12.61% 17.89%
OptionableYes Debt/Eq0.00 EPS Q/Q17.00% Profit Margin- Rel Volume1.26 Prev Close5.80
ShortableYes LT Debt/Eq2.16 EarningsMar 11 BMO Payout- Avg Volume656.23K Price5.39
Recom1.60 SMA2060.52% SMA50121.37% SMA200-16.59% Volume809,147 Change-7.07%
Feb-18-20Initiated Piper Sandler Overweight $12
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Jul-16-18Initiated Leerink Partners Outperform $24
Jul-16-18Initiated Jefferies Buy $23
May-26-20 10:11AM  Company News for May 26, 2020 Zacks -7.07%
May-22-20 08:00AM  Xeris Pharmaceuticals Announces Positive Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery Business Wire +28.04%
May-14-20 02:14PM  The President of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), Paul Edick, Just Bought 32% More Shares Simply Wall St.
03:00AM  Xeris Pharmaceuticals Signs Exclusive Agreement With Clinigen to Supply and Distribute Gvoke Outside the U.S on a Named Patient Basis Business Wire
May-09-20 05:02PM  Xeris Pharmaceuticals, Inc. (XERS) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 10:35AM  Xeris Pharmaceuticals Inc (XERS) Reports Q1 Loss, Lags Revenue Estimates Zacks +12.40%
09:36AM  Xeris' Shares March Higher, Can It Continue? Zacks
07:00AM  Xeris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Updates Business Wire
Apr-30-20 08:00AM  Xeris Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020 Business Wire
Apr-29-20 07:00AM  Xeris Extends $0 Copay for Gvoke PFS For People With Diabetes Through May 31, 2020 Business Wire +16.74%
Apr-28-20 06:43AM  Consumer group launches website to track all the public companies that got PPP small business loans Yahoo Finance +10.19%
Apr-20-20 08:00AM  Xeris Pharmaceuticals Announces Positive Topline Results From a Study of Its Novel Formulation of Diazepam Injection Business Wire
Mar-27-20 05:30PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire -10.09%
Mar-26-20 04:15PM  Xeris Pharmaceuticals Announces $0 Copay for Gvoke PFS for People With Diabetes Business Wire +21.28%
Mar-19-20 08:00AM  Xeris Pharmaceuticals Reinforces the Importance of GVOKE PFS for People With Diabetes Business Wire +13.42%
Mar-16-20 08:10AM  Xeris Pharmaceuticals, Inc. Just Reported Earnings, And Analysts Cut Their Target Price Simply Wall St. -31.74%
Mar-11-20 07:30AM  Xeris Pharmaceuticals, Inc. (XERS) Reports Q4 Loss, Tops Revenue Estimates Zacks +10.45%
06:00AM  Xeris Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline Progress Business Wire
Mar-04-20 12:30PM  Analysts Estimate Xeris Pharmaceuticals, Inc. (XERS) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-28-20 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Feb-27-20 04:05PM  Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 2020 GlobeNewswire -6.49%
Feb-20-20 04:05PM  Xeris Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Feb-18-20 09:00AM  Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference Business Wire +8.25%
Feb-12-20 09:18AM  The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga -6.93%
Feb-11-20 07:07PM  Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock GlobeNewswire -29.13%
Feb-10-20 04:06PM  Xeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock GlobeNewswire
Jan-31-20 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire +7.06%
Jan-07-20 07:57AM  The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering Benzinga +10.36%
Jan-06-20 05:01PM  Xeris Pharma stock rallies more than 20% on study results MarketWatch
04:05PM  Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise Business Wire
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-27-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-22-19 05:09PM  Hedge Funds Are Selling Xeris Pharmaceuticals, Inc. (XERS) Insider Monkey
Dec-11-19 07:21AM  The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Benzinga
Dec-10-19 05:33PM  Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery Business Wire
Dec-02-19 06:37AM  Trade Alert: The President Of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), Paul Edick, Has Just Spent US$153k Buying Shares Simply Wall St.
Nov-29-19 01:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-21-19 06:00AM  Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference GlobeNewswire
Nov-07-19 03:09PM  Is Xeris Pharmaceuticals, Inc. (XERS) A Good Stock To Buy? Insider Monkey -7.74%
11:45AM  Xeris Pharmaceuticals, Inc. (XERS) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:00AM  Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights GlobeNewswire
Nov-01-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +6.60%
Oct-30-19 10:33AM  Earnings Preview: Xeris Pharmaceuticals, Inc. (XERS) Q3 Earnings Expected to Decline Zacks
Oct-25-19 02:22PM  Does Xeris Pharmaceuticals (NASDAQ:XERS) Have A Healthy Balance Sheet? Simply Wall St.
Oct-01-19 08:00AM  Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors GlobeNewswire -5.29%
Sep-27-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-19-19 08:00AM  Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes Business Wire
Sep-10-19 11:58AM  UPDATE 2-Xeris Pharma's low blood sugar treatment wins FDA approval Reuters -10.97%
11:43AM  Xeris Pharma's low blood sugar treatment wins FDA approval Reuters
11:31AM  Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank Business Wire
11:30AM  Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia Business Wire
07:36AM  The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris Benzinga
Sep-04-19 11:34AM  Have Insiders Been Buying Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares? Simply Wall St. -5.85%
Aug-30-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire
Aug-29-19 05:00PM  Xeris Pharmaceuticals to Present at Two September Healthcare Conferences GlobeNewswire
Aug-06-19 07:45PM  Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Xeris Pharmaceuticals Announces Second Quarter 2019 Financial Results and Highlights GlobeNewswire
Aug-05-19 10:31AM  Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -5.58%
Aug-02-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire -6.20%
Jul-18-19 01:09PM  Did Changing Sentiment Drive Xeris Pharmaceuticals's (NASDAQ:XERS) Share Price Down By 38%? Simply Wall St.
Jun-28-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.42%
Jun-27-19 08:00AM  Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery Business Wire
Jun-17-19 08:00AM  Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon Business Wire +8.43%
May-25-19 09:03AM  Can We See Significant Institutional Ownership On The Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Share Register? Simply Wall St.
May-09-19 04:05PM  Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline GlobeNewswire +5.35%
May-01-19 08:00AM  Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam GlobeNewswire
Apr-26-19 04:01PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-29-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Mar-25-19 08:45AM  Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon Business Wire
Mar-14-19 04:15PM  Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia Business Wire
Mar-12-19 03:36PM  How Many Insiders Bought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares? Simply Wall St.
Mar-06-19 04:10PM  Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress GlobeNewswire
Mar-01-19 04:15PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-20-19 07:30AM  Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-13-19 07:26PM  Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock GlobeNewswire -8.67%
Feb-12-19 04:33PM  Why Molson Coors Brewing, Xeris Pharmaceuticals, and Varonis Systems Slumped Today Motley Fool -21.50%
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
Feb-11-19 04:05PM  Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock GlobeNewswire
Dec-20-18 08:30AM  European Medicines Agency Grants Orphan Drug Designation for Xeris Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS) Business Wire -11.96%
Nov-07-18 08:00AM  Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress GlobeNewswire
Oct-23-18 08:30AM  Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen Business Wire
Aug-17-18 08:30AM  Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris Novel Ready-to-Use Liquid Glucagon Business Wire
Aug-13-18 08:00AM  Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Jul-31-18 07:00AM  Xeris Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire
Jul-30-18 07:00AM  Xeris Pharmaceuticals Announces New Board Members and New Executive to Management Team GlobeNewswire
Jun-26-18 04:15PM  Xeris Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jun-25-18 04:15PM  Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen Business Wire
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 06:31PM  Xeris Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock GlobeNewswire
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that is in Phase II clinical trials for the treatment of congenital hyperinsulinism, post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, and hypoglycemia-associated autonomic failure, as well as for treating hypoglycemia associated with intermittent and chronic conditions, and bi-hormonal artificial pancreas closed-loop systems. In addition, it develops continuous subcutaneous glucagon infusion system of ready-to-use glucagon; ready-to-use diazepam formulation, which is in Phase I clinical trial for the treatment of acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is in pre-clinical stage for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shannon John Patrick JrSee RemarksMay 13Buy3.5522,00077,994117,493May 14 04:30 PM
Shannon John Patrick JrSee RemarksMay 08Buy3.207,88625,21995,493May 11 06:17 PM
Edick Paul RSee RemarksMay 08Buy3.0033,00099,000401,134May 11 05:06 PM
Hecht BethSee RemarksMar 13Buy1.974,0007,88057,083Mar 16 04:07 PM
Hecht BethSee RemarksFeb 14Buy4.154,00016,6008,083Feb 18 05:02 PM
Shannon John Patrick JrSee RemarksFeb 14Buy4.1512,04849,99922,607Feb 18 05:02 PM
Edick Paul RSee RemarksFeb 14Buy4.1520,00083,000183,134Feb 18 05:02 PM
JOHNSON KENNETH ERLANDSee RemarksFeb 14Buy4.152,41010,0026,115Feb 18 04:59 PM
Deutsch Barry M.See RemarksFeb 14Buy4.159,63940,00239,359Feb 18 04:55 PM
PRESTRELSKI STEVENChief Scientific OfficerJan 13Sale5.5010,00054,992421,824Jan 14 04:40 PM
Edick Paul RSee RemarksNov 25Buy8.5517,935153,283172,935Nov 27 04:43 PM